1
|
El-Nagar MKS, Shahin MI, El-Behairy MF, Taher ES, El-Badawy MF, Sharaky M, Abou El Ella DA, Abouzid KAM, Adel M. Pyridazinone-based derivatives as anticancer agents endowed with anti-microbial activity: molecular design, synthesis, and biological investigation. RSC Med Chem 2024:d4md00481g. [PMID: 39246752 PMCID: PMC11375954 DOI: 10.1039/d4md00481g] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2024] [Accepted: 08/14/2024] [Indexed: 09/10/2024] Open
Abstract
Cancer patients undergoing chemotherapy are highly susceptible to infections owing to their compromised immune system, which also promotes cancer progression through inflammation. Thus, this study aimed to develop novel chemotherapeutic agents with both anticancer and antimicrobial properties. A series of diarylurea derivatives based on pyridazinone scaffolds were designed, synthesized, and characterized as surrogates for sorafenib. The synthesized compounds were tested for their antimicrobial activity and screened against 60 cancer cell lines at the National Cancer Institute (NCI). Compound 10h exhibited potent antibacterial activity against Staphylococcus aureus (MIC = 16 μg mL-1), whereas compound 8g showed significant antifungal activity against Candida albicans (MIC = 16 μg mL-1). Additionally, ten compounds were further evaluated for VEGFR-2 inhibition, with compound 17a showing the best inhibitory activity. Compounds 8f, 10l, and 17a demonstrated significant anticancer activity against melanoma, NSCLC, prostate cancer, and colon cancer, with growth inhibition percentages (GI%) ranging from 62.21% to 100.14%. Compounds 10l and 17a were selected for five-dose screening, displaying GI50 values of 1.66-100 μM. Compound 10l induced G0-G1 phase cell cycle arrest in the A549/ATCC cell line, increasing the cell population from 85.41% to 90.86%. Gene expression analysis showed that compound 10l upregulated pro-apoptotic genes p53 and Bax and downregulated the anti-apoptotic gene Bcl-2. Molecular docking studies provided insights into the binding modes of the compounds to the VEGFR-2 enzyme. In conclusion, the pyridazinone-based diarylurea derivatives developed in this study show promise as dual-function antimicrobial and anticancer agents, warranting further investigation.
Collapse
Affiliation(s)
- Mohamed K S El-Nagar
- Department of Organic and Medicinal Chemistry, Faculty of Pharmacy, University of Sadat City Sadat City Menoufia 32897 Egypt
| | - Mai I Shahin
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Ain Shams University Abbassia Cairo 11566 Egypt
| | - Mohammed F El-Behairy
- Department of Organic and Medicinal Chemistry, Faculty of Pharmacy, University of Sadat City Sadat City Menoufia 32897 Egypt
| | - Ehab S Taher
- Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Al-Azhar University Assiut 71524 Egypt
- Department of Basic Medical and Dental Sciences, Faculty of Dentistry, Zarqa University Zarqa 13110 Jordan
| | - Mohamed F El-Badawy
- Department of Microbiology and Immunology, Faculty of Pharmacy, University of Sadat City Sadat City Menoufia 32897 Egypt
| | - Marwa Sharaky
- Department of Cancer Biology, Pharmacology Unit, National Cancer Institute (NCI), Cairo University Cairo Egypt
| | - Dalal A Abou El Ella
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Ain Shams University Abbassia Cairo 11566 Egypt
| | - Khaled A M Abouzid
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Ain Shams University Abbassia Cairo 11566 Egypt
| | - Mai Adel
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Ain Shams University Abbassia Cairo 11566 Egypt
| |
Collapse
|
2
|
Sabt A, Eldehna WM, Al-Warhi T, Alotaibi OJ, Elaasser MM, Suliman H, Abdel-Aziz HA. Discovery of 3,6-disubstituted pyridazines as a novel class of anticancer agents targeting cyclin-dependent kinase 2: synthesis, biological evaluation and in silico insights. J Enzyme Inhib Med Chem 2021; 35:1616-1630. [PMID: 32781872 PMCID: PMC7470104 DOI: 10.1080/14756366.2020.1806259] [Citation(s) in RCA: 38] [Impact Index Per Article: 12.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022] Open
Abstract
Human health in the current medical era is facing numerous challenges, especially cancer. So, the therapeutic arsenal for cancer should be unremittingly enriched with novel small molecules that selectively target tumour cells with minimal toxicity towards normal cells. In this context, herein a new series of 3,6-disubstituted pyridazines 11a–r has been synthesised and evaluated for in vitro anticancer activity. They possessed good anti-proliferative action towards human breast cancer T-47D (IC50 range: 0.43 ± 0.01 − 35.9 ± 1.18 µM) and MDA-MB-231 (IC50 range: 0.99 ± 0.03 − 34.59 ± 1.13 µM) cell lines, whereas they displayed weak activity against the tested ovarian cancer cell line SKOV-3. Among the studied compounds, the methyltetrahydropyran-bearing pyridazine 11m emerged as the unique submicromolar growth inhibitor herein reported towards both T-47D (IC50 = 0.43 ± 0.01 µM) and MDA-MB-231 (IC50 = 0.99 ± 0.03 µM) cell lines. In addition, the biological results indicated that pyridazines 11l and 11m exerted an efficient alteration within the cell cycle progression as well as induction of apoptosis in both T-47D and MDA-MB-231 cells. Moreover, pyridazines 11l and 11m displayed good mean tumour S. I. values of 13.7 and 16.1 upon assessment of their cytotoxicity towards non-tumorigenic breast MCF-10A cells. Furthermore, an in silico study proposed CDK2 as a probable enzymatic target for pyridazines 11, and explored their binding interactions within the vicinity of CDK2 binding site. Subsequently, pyridazines 11e, 11h, 11l, and 11m were selected to be evaluated for their ability to inhibit CDK2, where they exerted good inhibitory activity (IC50 = 151, 43.8, 55.6 and 20.1 nM, respectively). Finally, the in silico study implied that target pyridazines 11 exhibited not only an efficient anticancer activity but also an acceptable ADME, physicochemical and druglikeness properties, specifically pyridazines 11l and 11m. Overall the obtained results from this study quite sustained our strategy and gave us a robust opportunity for further development and optimisation of 3,6-disubstituted pyridazine scaffold to enrich therapeutic arsenal with efficient and safe anticancer CDK inhibitors.
Collapse
Affiliation(s)
- Ahmed Sabt
- Chemistry of Natural Compounds Department, National Research Centre, Dokki, Egypt
| | - Wagdy M Eldehna
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Kafrelsheikh University, Kafrelsheikh, Egypt
| | - Tarfah Al-Warhi
- Department of Chemistry, College of Science, Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia
| | - Ohoud J Alotaibi
- Department of Chemistry, College of Science, Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia
| | - Mahmoud M Elaasser
- The Regional Center for Mycology and Biotechnology, Al-Azhar University, Cairo, Egypt
| | - Howayda Suliman
- Department of Medical Biochemistry, Faculty of Medicine, Alexandria University, Alexandria, Egypt
| | - Hatem A Abdel-Aziz
- Department of Applied Organic Chemistry, National Research Center, Giza, Egypt
| |
Collapse
|
3
|
Sengmany S, Sitter M, Léonel E, Le Gall E, Loirand G, Martens T, Dubreuil D, Dilasser F, Rousselle M, Sauzeau V, Lebreton J, Pipelier M, Le Guével R. Synthesis and biological evaluation of 3-amino-, 3-alkoxy- and 3-aryloxy-6-(hetero)arylpyridazines as potent antitumor agents. Bioorg Med Chem Lett 2018; 29:755-760. [PMID: 30655216 DOI: 10.1016/j.bmcl.2018.12.050] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2018] [Revised: 11/29/2018] [Accepted: 12/03/2018] [Indexed: 01/06/2023]
Abstract
Various 3-amino-, 3-aryloxy- and alkoxy-6-arylpyridazines have been synthesized by an electrochemical reductive cross-coupling between 3-amino-, 3-aryloxy- or 3-alkoxy-6-chloropyridazines and aryl or heteroaryl halides. In vitro antiproliferative activity of these products was evaluated against a representative panel of cancer cell lines (HuH7, CaCo-2, MDA-MB-231, HCT116, PC3, NCI-H727, HaCaT) and oncogenicity prevention of the more efficient derivatives was highlighted on human breast cancer cell line MDA-MB 468-Luc prior establishing their interaction with p44/42 and Akt-dependent signaling pathways.
Collapse
Affiliation(s)
- Stéphane Sengmany
- Electrochimie et Synthèse Organique, Université Paris Est, ICMPE (UMR 7182), CNRS, UPEC, 2 rue Henri Dunant, F-94320 Thiais, France
| | - Mathilde Sitter
- Electrochimie et Synthèse Organique, Université Paris Est, ICMPE (UMR 7182), CNRS, UPEC, 2 rue Henri Dunant, F-94320 Thiais, France
| | - Eric Léonel
- Electrochimie et Synthèse Organique, Université Paris Est, ICMPE (UMR 7182), CNRS, UPEC, 2 rue Henri Dunant, F-94320 Thiais, France.
| | - Erwan Le Gall
- Electrochimie et Synthèse Organique, Université Paris Est, ICMPE (UMR 7182), CNRS, UPEC, 2 rue Henri Dunant, F-94320 Thiais, France
| | - Gervaise Loirand
- INSERM, UMR1087, CNRS, UNIV Nantes, l'institut du thorax, 8 quai Moncousu - BP 70721, F-44007 Nantes Cedex 1, France
| | - Thierry Martens
- Electrochimie et Synthèse Organique, Université Paris Est, ICMPE (UMR 7182), CNRS, UPEC, 2 rue Henri Dunant, F-94320 Thiais, France
| | - Didier Dubreuil
- Laboratoire de Synthèse Organique, Chimie et Interdisciplinarité: Synthèse, Analyse, Modélisation, UMR 6513, CNRS-Université de Nantes, 2 rue de la Houssinière, BP 92208, F-44322 Nantes Cedex 3, France
| | - Florian Dilasser
- INSERM, UMR1087, CNRS, UNIV Nantes, l'institut du thorax, 8 quai Moncousu - BP 70721, F-44007 Nantes Cedex 1, France
| | - Morgane Rousselle
- INSERM, UMR1087, CNRS, UNIV Nantes, l'institut du thorax, 8 quai Moncousu - BP 70721, F-44007 Nantes Cedex 1, France
| | - Vincent Sauzeau
- INSERM, UMR1087, CNRS, UNIV Nantes, l'institut du thorax, 8 quai Moncousu - BP 70721, F-44007 Nantes Cedex 1, France
| | - Jacques Lebreton
- Laboratoire de Synthèse Organique, Chimie et Interdisciplinarité: Synthèse, Analyse, Modélisation, UMR 6513, CNRS-Université de Nantes, 2 rue de la Houssinière, BP 92208, F-44322 Nantes Cedex 3, France
| | - Muriel Pipelier
- Laboratoire de Synthèse Organique, Chimie et Interdisciplinarité: Synthèse, Analyse, Modélisation, UMR 6513, CNRS-Université de Nantes, 2 rue de la Houssinière, BP 92208, F-44322 Nantes Cedex 3, France
| | - Rémy Le Guével
- Plate-Forme ImPACcell, Structure Fédérative de Recherche BIOSIT, Université de Rennes 1, Campus de Villejean, 2 Avenue du Pr. Leon Bernard CS34317, F-35043 Rennes Cedex, France
| |
Collapse
|
4
|
Rafi UM, Mahendiran D, Haleel AK, Nankar RP, Doble M, Rahiman AK. New pyridazine-based binuclear nickel(ii), copper(ii) and zinc(ii) complexes as prospective anticancer agents. NEW J CHEM 2016. [DOI: 10.1039/c5nj02739j] [Citation(s) in RCA: 50] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
The complexes containing diethylamino substituents exhibit promising cytotoxicity against the estrogen receptor (ER) negative MDA-MB-231 breast cancer cell line.
Collapse
Affiliation(s)
- Ummer Muhammed Rafi
- Post-Graduate and Research Department of Chemistry
- The New College (Autonomous)
- Chennai-600 014
- India
| | - Dharmasivam Mahendiran
- Post-Graduate and Research Department of Chemistry
- The New College (Autonomous)
- Chennai-600 014
- India
| | - Azees Khan Haleel
- Post-Graduate and Research Department of Chemistry
- The New College (Autonomous)
- Chennai-600 014
- India
| | - Rakesh Pandeet Nankar
- Bioengineering and Drug Design Lab
- Department of Biotechnology
- Indian Institute of Technology Madras
- Chennai-600 036
- India
| | - Mukesh Doble
- Bioengineering and Drug Design Lab
- Department of Biotechnology
- Indian Institute of Technology Madras
- Chennai-600 036
- India
| | - Aziz Kalilur Rahiman
- Post-Graduate and Research Department of Chemistry
- The New College (Autonomous)
- Chennai-600 014
- India
| |
Collapse
|
5
|
Müller SG, Heckel A, Kley JT, Lehmann T, Lustenberger P, Oost T, Roth GJ, Rudolf K, Arndt K, Lenter M, Lotz RR, Maier GM, Markert M, Schindler M, Stenkamp D. Design, synthesis and evaluation of MCH receptor 1 antagonists—Part I: Optimization of HTS hits towards an in vivo efficacious tool compound BI 414. Bioorg Med Chem Lett 2015; 25:3264-9. [DOI: 10.1016/j.bmcl.2015.05.077] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2015] [Revised: 05/22/2015] [Accepted: 05/24/2015] [Indexed: 12/14/2022]
|
6
|
Oost T, Heckel A, Kley JT, Lehmann T, Müller S, Roth GJ, Rudolf K, Arndt K, Budzinski R, Lenter M, Lotz RRH, Maier GM, Markert M, Thomas L, Stenkamp D. Design, synthesis and evaluation of MCH receptor 1 antagonists--Part III: Discovery of pre-clinical development candidate BI 186908. Bioorg Med Chem Lett 2015; 25:3275-80. [PMID: 26105194 DOI: 10.1016/j.bmcl.2015.05.065] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2015] [Revised: 05/22/2015] [Accepted: 05/24/2015] [Indexed: 11/24/2022]
Abstract
Although overweight and obesity are highly prevalent conditions, options to treat them are still very limited. As part of our search for safe and effective MCH-R1 antagonists for the treatment of obesity, two series of pyridones and pyridazinones were evaluated. Optimization was aimed at improving DMPK properties by increasing metabolic stability and improving the safety profile by reducing inhibition of the hERG channel and reducing the potential to induce phospholipidosis. Steric shielding of a labile keto moiety with an ortho-methyl group and fine-tuning of the polarity in several parts of the molecule resulted in BI 186908 (11 g), a potent and selective MCH-R1 antagonist with favorable DMPK and CMC properties. Chronic administration of BI 186908 resulted in significant body weight reduction comparable to sibutramine in a 4 week diet-induced obesity model in rats. Based on its favorable safety profile, BI 186908 was advanced to pre-clinical development.
Collapse
Affiliation(s)
- Thorsten Oost
- Boehringer Ingelheim Pharma GmbH & Co. KG, Department of Medicinal Chemistry, Research Germany, Birkendorfer Str. 65, 88397 Biberach an der Riss, Germany.
| | - Armin Heckel
- Boehringer Ingelheim Pharma GmbH & Co. KG, Department of Medicinal Chemistry, Research Germany, Birkendorfer Str. 65, 88397 Biberach an der Riss, Germany
| | - Jörg T Kley
- Boehringer Ingelheim Pharma GmbH & Co. KG, Department of Medicinal Chemistry, Research Germany, Birkendorfer Str. 65, 88397 Biberach an der Riss, Germany
| | - Thorsten Lehmann
- Boehringer Ingelheim Pharma GmbH & Co. KG, Department of Medicinal Chemistry, Research Germany, Birkendorfer Str. 65, 88397 Biberach an der Riss, Germany
| | - Stephan Müller
- Boehringer Ingelheim Pharma GmbH & Co. KG, Department of Medicinal Chemistry, Research Germany, Birkendorfer Str. 65, 88397 Biberach an der Riss, Germany
| | - Gerald J Roth
- Boehringer Ingelheim Pharma GmbH & Co. KG, Department of Medicinal Chemistry, Research Germany, Birkendorfer Str. 65, 88397 Biberach an der Riss, Germany
| | - Klaus Rudolf
- Boehringer Ingelheim Pharma GmbH & Co. KG, Department of Medicinal Chemistry, Research Germany, Birkendorfer Str. 65, 88397 Biberach an der Riss, Germany
| | - Kirsten Arndt
- Boehringer Ingelheim Pharma GmbH & Co. KG, Department of Cardiometabolic Research, Research Germany, Birkendorfer Str. 65, 88397 Biberach an der Riss, Germany
| | - Ralph Budzinski
- Boehringer Ingelheim Pharma GmbH & Co. KG, Department of Cardiometabolic Research, Research Germany, Birkendorfer Str. 65, 88397 Biberach an der Riss, Germany
| | - Martin Lenter
- Boehringer Ingelheim Pharma GmbH & Co. KG, Department of Cardiometabolic Research, Research Germany, Birkendorfer Str. 65, 88397 Biberach an der Riss, Germany
| | - Ralf R H Lotz
- Boehringer Ingelheim Pharma GmbH & Co. KG, Department of Drug Discovery Support, Research Germany, Birkendorfer Str. 65, 88397 Biberach an der Riss, Germany
| | - Gerd-Michael Maier
- Boehringer Ingelheim Pharma GmbH & Co. KG, Department of Drug Discovery Support, Research Germany, Birkendorfer Str. 65, 88397 Biberach an der Riss, Germany
| | - Michael Markert
- Boehringer Ingelheim Pharma GmbH & Co. KG, Department of Drug Discovery Support, Research Germany, Birkendorfer Str. 65, 88397 Biberach an der Riss, Germany
| | - Leo Thomas
- Boehringer Ingelheim Pharma GmbH & Co. KG, Department of Cardiometabolic Research, Research Germany, Birkendorfer Str. 65, 88397 Biberach an der Riss, Germany
| | - Dirk Stenkamp
- Boehringer Ingelheim Pharma GmbH & Co. KG, Department of Medicinal Chemistry, Research Germany, Birkendorfer Str. 65, 88397 Biberach an der Riss, Germany
| |
Collapse
|